Jennifer P. King

Jennifer P. King

Auto-generated profile, based on publicly available information

Jennifer P. King

Marshfield Clinic Research Institute

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
EBEdward A Belongia
Edward A Belongia
MSMelissa D Simpson
Melissa D Simpson
JKJennifer P King
Jennifer P King
MSMaria E Sundaram
Maria E Sundaram
NKNicholas S Kelley
Nicholas S Kelley
HMHuong Q McLean
Huong Q McLean

1 March 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
MMMichael M. McNeil
Michael M. McNeil
EWEric S. Weintraub
Eric S. Weintraub
JDJonathan Duffy
Jonathan Duffy
LSLakshmi Sukumaran
Lakshmi Sukumaran
SJSteven J. Jacobsen
Steven J. Jacobsen
FDFrank DeStefano
Frank DeStefano
Anaphylaxis is a potentially life-threatening allergic reaction. The risk of anaphylaxis after vaccination has not been well described in adults or with newer vaccines in children. We sought to estimate the incidence of anaphylaxis after vaccines and describe the demographic and clinical characteristics of confirmed cases of anaphylaxis. Using health care data from the Vaccine Safety Datalink, we determined rates of anaphylaxis after vaccination in children and adults. We first identified all patients with a vaccination record from January 2009 through December 2011 and used diagnostic and procedure codes to identify potential anaphylaxis cases. Medical records of potential cases were reviewed. Confirmed cases met the Brighton Collaboration definition for anaphylaxis and had to be determined to be vaccine triggered. We calculated the incidence of anaphylaxis after all vaccines combined and for selected individual vaccines. We identified 33 confirmed vaccine-triggered anaphylaxis cases that occurred after 25,173,965 vaccine doses. The rate of anaphylaxis was 1.31 (95% CI, 0.90-1.84) per million vaccine doses. The incidence did not vary significantly by age, and there was a nonsignificant female predominance. Vaccine-specific rates included 1.35 (95% CI, 0.65-2.47) per million doses for inactivated trivalent influenza vaccine (10 cases, 7,434,628 doses given alone) and 1.83 (95% CI, 0.22-6.63) per million doses for inactivated monovalent influenza vaccine (2 cases, 1,090,279 doses given alone). The onset of symptoms among cases was within 30 minutes (8 cases), 30 to less than 120 minutes (8 cases), 2 to less than 4 hours (10 cases), 4 to 8 hours (2 cases), the next day (1 case), and not documented (4 cases). Anaphylaxis after vaccination is rare in all age groups. Despite its rarity, anaphylaxis is a potentially life-threatening medical emergency that vaccine providers need to be prepared to treat.

20 October 2015 in JAMA
Verified
Journal Article
Open access
PDF file
LSLakshmi Sukumaran
Lakshmi Sukumaran
NMNatalie L. McCarthy
Natalie L. McCarthy
EKElyse O. Kharbanda
Elyse O. Kharbanda
MMMichael M. McNeil
Michael M. McNeil
ANAllison L. Naleway
Allison L. Naleway
SOSaad B. Omer
Saad B. Omer
Pertussis (whooping cough) is a vaccine-preventable illness that has been increasing in incidence over the past decade in the United States.1-3 Neonates and infants are at increased risk of pertussis-related hospitalization and death compared with older children and adults. Many public health strategies have been recommended to decrease the burden of pertussis in neonates and infants.4-6 Most recently, in 2012, the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommended tetanus, diphtheria, and acellular pertussis (Tdap) vaccination for all pregnant women during each pregnancy regardless of prior immunization status.6

1 November 2015 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
LSLakshmi Sukumaran
Lakshmi Sukumaran
NMNatalie L. McCarthy
Natalie L. McCarthy
EKElyse O. Kharbanda
Elyse O. Kharbanda
EWEric S. Weintraub
Eric S. Weintraub
GVGabriela Vazquez-Benitez
Gabriela Vazquez-Benitez
WOWalter A. Orenstein
Walter A. Orenstein
OBJECTIVE: To evaluate the safety of coadministering tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) and influenza vaccines during pregnancy by comparing adverse events after concomitant and sequential vaccination. METHODS: We conducted a retrospective cohort study of pregnant women aged 14–49 years in the Vaccine Safety Datalink from January 1, 2007, to November 15, 2013. We compared medically attended acute events (fever, any acute reaction) and adverse birth outcomes (preterm delivery, low birth weight, small for gestational age) in women receiving concomitant Tdap and influenza vaccination and women receiving sequential vaccination. RESULTS: Among 36,844 pregnancies in which Tdap and influenza vaccines were administered, the vaccines were administered concomitantly in 8,464 (23%) pregnancies and sequentially in 28,380 (77%) pregnancies. Acute adverse events after vaccination were rare. We found no statistically significant increased risk of fever or any medically attended acute adverse event in pregnant women vaccinated concomitantly compared with sequentially. When analyzing women at 20 weeks of gestation or greater during periods of influenza vaccine administration, there were no differences in preterm delivery, low-birth-weight, or small-for-gestational-age neonates between women vaccinated concomitantly compared with sequentially in pregnancy. CONCLUSION: Concomitant administration of Tdap and influenza vaccines during pregnancy was not associated with a higher risk of medically attended adverse acute outcomes or birth outcomes compared with sequential vaccination. LEVEL OF EVIDENCE: II

26 May 2012 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
MWMichael S. Wolf
Michael S. Wolf
JKJennifer King
Jennifer King
KJKara Jacobson
Kara Jacobson
LFLorenzo Di Francesco
Lorenzo Di Francesco
SBStacy Cooper Bailey
Stacy Cooper Bailey
RPRuth M. Parker
Ruth M. Parker

1 September 2017 in Vaccine
Verified
Journal Article
Closed access
JDJames G. Donahue
James G. Donahue
BKBurney A. Kieke
Burney A. Kieke
JKJennifer P. King
Jennifer P. King
FDFrank DeStefano
Frank DeStefano
MMMaria A. Mascola
Maria A. Mascola
EBEdward A. Belongia
Edward A. Belongia